Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
I3-MaC Study
2024-513251-32-00Phase 4Withdrawn
- Sponsor
- Azienda Ospedaliero-Universitaria Policlinico Umberto I
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of iomeprol in breast cancer, sponsored by Azienda Ospedaliero-Universitaria Policlinico Umberto I. Primary endpoints: Dose of contrast administered, Contrast flow rate and 7 more. Planned start Jul 2024; status: withdrawn.
02
Drugs
iomeprol
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-513251-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513251-32-00.